Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities

 
• By Emily Hayes
  
BMY Chief Scientific Officer Thomas Lynch
Bristol's Chief Scientific Officer Thomas Lynch • Source: Bristol-Myers Squibb

More from Immuno-oncology

More from Anticancer